[Chemotherapy for the patients with esophageal cancer].
The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma. Paclitaxel has shown favorable results as a single agent or in combination with cisplatin. The efficacy of neoadjuvant chemotherapy in terms of survival benefit remains controversial despite large-scale, randomized, controlled trials comparing it with surgery alone. The disease-free survival benefit of postoperative adjuvant chemotherapy was recognized in a Japan Clinical Oncology Group randomized controlled trial in comparison with surgery alone.
Ando
Nobutoshi
N
Department of Surgery, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan.
Shih
Chih-Horng
CH
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage
D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin